<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02283099</url>
  </required_header>
  <id_info>
    <org_study_id>UKE-DZIF2-VSV{Delta}G/ZEBOVGP</org_study_id>
    <nct_id>NCT02283099</nct_id>
  </id_info>
  <brief_title>Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)</brief_title>
  <official_title>An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSVΔG-ZEBOV-GP (BPSC1001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Center for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center North</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, University of Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KEMRI-Wellcome Trust Collaborative Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to establish safety, tolerability and immunogenicity of rVSVΔG-ZEBOV-GP&#xD;
      (BPSC1001), an Ebola Virus Vaccine candidate (recombinant vesicular stomatitis virus (VSV)&#xD;
      expressing the envelope glycoprotein of Ebola Virus Zaire), investigated at three different&#xD;
      dose levels in 30 healthy adults in Germany. This study is part of the WHO led VEBCON&#xD;
      consortium that is aiming to generate harmonized data for the rVSVΔG-ZEBOV-GP (BPSC1001)&#xD;
      vaccine candidate to allow optimized rapid decisions on dose and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to assess safety and immunogenicity of an experimental ebola&#xD;
      vaccine.&#xD;
&#xD;
      An outbreak due to the Ebola Zaire (ZEBOV) strain of unprecedented magnitude and scope and&#xD;
      with a high mortality continues to spread across West Africa. No vaccine is currently&#xD;
      licensed.&#xD;
&#xD;
      The specific opportunity at hand with rVSVΔG-ZEBOV-GP (BPSC1001) is to achieve long-lasting&#xD;
      protective immunity to ZEBOV on a time scale of weeks in humans upon a single-shot&#xD;
      vaccination, offering a discrete benefit over prime-boost vaccination protocols. The current&#xD;
      outbreak represents a global health emergency and the need for access to therapeutic&#xD;
      intervention and vaccines is paramount.&#xD;
&#xD;
      The vaccine investigated in this study might provide a critical tool to suppress future&#xD;
      out-breaks of EVD in areas at risk.&#xD;
&#xD;
      This study is 1 of 4 clinical trials currently conducted as part of the WHO-led VEBCON&#xD;
      consortium, aiming to generate harmonized data for the rVSVΔG-ZEBOV-GP (BPSC1001) vaccine&#xD;
      candidate to allow optimized rapid decisions on dose and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of adverse events associated with the rVSVΔ-ZEBOV-GP (BPSC1001) vaccine will be collected and measured</measure>
    <time_frame>Vaccination (day 0) to day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ZEBOV-GP-specific antibody responses</measure>
    <time_frame>Vaccination (day 0) to day 180</time_frame>
    <description>Humoral immunity: Magnitude of ZEBOV-GP-specific antibody responses as assayed by ELISA in a centralized laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate vaccine viremia and excretion</measure>
    <time_frame>Vaccination (day 0) to day 28</time_frame>
    <description>Vaccine viremia and viral shedding: concentration of rVSV in peripheral blood, urine and saliva as detected by qRT-PCR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hemorrhagic Fever, Ebola</condition>
  <arm_group>
    <arm_group_label>rVSVΔ-ZEBOV-GP (BPSC1001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSVΔ-ZEBOV-GP</intervention_name>
    <description>single dose of rVSVΔ-ZEBOV-GP (3x10^6 pfu, 2x10^7 pfu or 3x10^5)</description>
    <arm_group_label>rVSVΔ-ZEBOV-GP (BPSC1001)</arm_group_label>
    <other_name>BPSC1001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand the subject information and to personally sign the informed&#xD;
             consent&#xD;
&#xD;
          -  Provided written informed consent.&#xD;
&#xD;
          -  Healthy females and males aged 18 - 55 years .&#xD;
&#xD;
          -  No clinically significant health problems&#xD;
&#xD;
          -  Body mass index 18.5 - 30.0 kg/m2 and weight &gt;50 kg at screening.&#xD;
&#xD;
          -  Females of childbearing potential who agree to comply with the applicable&#xD;
             contraceptive requirements of the protocol or females who are permanently sterilized.&#xD;
&#xD;
          -  Males who agree to comply with the applicable contraceptive requirements of the&#xD;
             protocol&#xD;
&#xD;
          -  Subjects must be willing to minimize blood and body fluid exposure of others for 7&#xD;
             days after vaccination&#xD;
&#xD;
          -  Be willing to refrain from blood donation during the course of the study.&#xD;
&#xD;
          -  The subject is co-operative and available for the entire study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior receipt of an Ebolavirus or Marburgvirus vaccine or VSV-vectored vaccine.&#xD;
&#xD;
          -  Receipt of any vaccine in the 2 weeks prior to the trial vaccination (4 weeks for live&#xD;
             vaccines) or planned receipt of any vaccine in the 3 weeks following the trial&#xD;
             vaccination.&#xD;
&#xD;
          -  Known allergy to the components of the BPSC1001 vaccine product or history of&#xD;
             life-threatening reactions to vaccine containing the same substances.&#xD;
&#xD;
          -  Participation in a clinical trial or use of an investigational product within 30 days&#xD;
             or five times the half-life of the investigational drug -prior to receiving the first&#xD;
             dose within this study&#xD;
&#xD;
          -  Evidence in the subject's medical history or in the medical examination that might&#xD;
             influence either the safety of the subject or the absorption, distribution, metabolism&#xD;
             or excretion of the investigational product under investigation.&#xD;
&#xD;
          -  Any positive result for HIV1/2, HCV antibody or HBs antigen testing.&#xD;
&#xD;
          -  Pregnant or lactating females, or females who intend to become pregnant during the&#xD;
             study period.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic&#xD;
             therapy in the previous 5 years, and/or diabetes&#xD;
&#xD;
          -  Subjects with inflammatory, infectious and neuroinflammatory underlying disease which&#xD;
             could cause an expected impairment of the blood brain barrier such as meningitis,&#xD;
             multiple sclerosis, epilepsy, or Alzheimer's.&#xD;
&#xD;
          -  Any household contact who is immunodeficient, HIV positive or pregnant&#xD;
&#xD;
          -  Working with livestock&#xD;
&#xD;
          -  Any chronic or active neurologic disorder, including migraines, seizures, and&#xD;
             epilepsy, exclud-ing a single febrile seizure as a child&#xD;
&#xD;
          -  Known history of Guillain-Barré Syndrome&#xD;
&#xD;
          -  Active malignancy or history of metastatic or hematologic malignancy&#xD;
&#xD;
          -  Suspected or known alcohol and/or illicit drug abuse within the past 5 years&#xD;
&#xD;
          -  Moderate or severe illness and/or fever &gt;38°C within 1 week prior to vaccination&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 120 days&#xD;
             preceding study entry or planned administration during the study period&#xD;
&#xD;
          -  History of blood donation within 60 days of enrollment or plans to donate within the&#xD;
             study period&#xD;
&#xD;
          -  Receipt of chronic immune suppressants or other immune-modifying drugs within 6 months&#xD;
             of study inclusion&#xD;
&#xD;
          -  Subjects with skin lesions close to the injection site or active oral lesions will be&#xD;
             excluded.&#xD;
&#xD;
          -  Thrombocytopenia, contraindicating intramuscular vaccination based on investigator's&#xD;
             judgment&#xD;
&#xD;
          -  Subjects with a significant infection or known inflammation.&#xD;
&#xD;
          -  History of relevant cardiovascular disorders or evidence of hyper- or hypotension&#xD;
&#xD;
          -  Subjects who are known or suspected not to comply with the study directives.&#xD;
&#xD;
          -  Any other significant finding that in the opinion of the investigator would increase&#xD;
             the risk of the individual having an adverse outcome from participating in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marylyn M. Addo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTC North GmbH &amp; Co. KG</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola virus, vaccination, phase I, healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

